Skip to content
value.today

Alzheon, Inc.

Total raised
$251 M
9 rounds on record
Latest round
$79 M
Aug 2026
First round on record
Dec 2014
Today
Private
No later event on record

Funding rounds

9 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Alzheon, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$79 MNo. 9$50 to $250 million

Alzheon, Inc.: Raise no. 9, Aug 2026

Investors in this round

3 investors had bought by the notice of Sep 10, 2026: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$79 M of $500 M offered; $421 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adem K. Albayrak · Executive Officer · Chief Data Officer
  • Aidan K. Power, MRCPsych · Executive Officer · Chief Development Officer
  • John K. Hey, Ph.D. · Executive Officer · Chief Scientific Officer
  • Kenneth K. Mace · Executive Officer · Treasurer and Chief Financial Officer
  • Martin Tolar, M.D., Ph.D. · Executive Officer, Director · President and Chief Executive Officer
  • Susan K. Abushakra, M.D. · Executive Officer · Chief Medical Officer
  • Christopher Noel Dunn · Director
  • Diane K. Jorkasky, M.D. · Director
  • Gino K. Santini · Director
  • Jordan W. Heller · Director
  • Muneer K. Satter · Director
  • Neil W. Flanzraich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Martin Tolar, M.D., Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 10, 2026. Read the notice at the SEC.

equitySEC
Feb 2024$126 MNo. 8$50 to $250 million

Alzheon, Inc.: Raise no. 8, Feb 2024

Investors in this round

76 investors had bought by the notice of Feb 10, 2025: 76 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$126 M of $150 M offered; $24 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adem E. Albayrak · Executive Officer · Chief Data Officer
  • Aidan K. Power, MRCPsych · Executive Officer · Chief Development Officer
  • Glenn E. Pauly · Executive Officer · Chief Commercial Officer
  • John K. Hey, Ph.D. · Executive Officer · Chief Scientific Officer
  • Kenneth A. Mace · Executive Officer · Treasurer and Chief Financial Officer
  • Martin Tolar, M.D., Ph.D. · Executive Officer, Director · President and Chief Executive Officer
  • Susan K. Abushakra, M.D. · Executive Officer · Chief Medical Officer
  • Christopher Noel Dunn · Director
  • Diane K. Jorkasky, M.D. · Director
  • Gino K. Santini · Director
  • Jordan W. Heller · Director
  • Muneer E. Satter · Director
  • Neil W. Flanzraich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Martin Tolar, M.D., Ph.D., President and Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Feb 10, 2025. Read the notice at the SEC.

equitySEC
Dec 2022$2 MNo. 7Under $2 million

Alzheon, Inc.: Raise no. 7, Dec 2022

Investors in this round

6 investors had bought by the notice of Jan 11, 2023: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $50 M offered; $48 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aidan K. Power, MRCPsych · Executive Officer · Chief Development Officer
  • John K. Hey, Ph.D. · Executive Officer · Chief Scientific Officer
  • Kenneth A. Mace · Executive Officer · Treasurer and Chief Financial Officer
  • Martin Tolar, M.D., Ph.D. · Director, Executive Officer · President and Chief Executive Officer
  • Susan K. Abushakra, M.D. · Executive Officer · Chief Medical Officer
  • Christopher Noel Dunn · Director
  • Diane K. Jorkasky, M.D. · Director
  • Jordan W. Heller · Director
  • Neil W. Flanzraich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Martin Tolar, M.D., Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 11, 2023. Read the notice at the SEC.

equitySEC
Sep 2020$2 MNo. 6$2 to $10 million

Alzheon, Inc.: Raise no. 6, Sep 2020

Investors in this round

5 investors had bought by the notice of Sep 30, 2020: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $50 M offered; $48 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John K. Hey, Ph.D. · Executive Officer
  • Kenneth A. Mace · Executive Officer · Treasurer/VP Finance
  • Martin Tolar, M.D., Ph.D. · Director, Executive Officer · President and Chief Executive Officer
  • Susan K. Abushakra, M.D. · Executive Officer
  • Diane K. Jorkasky, M.D. · Director
  • Jordan W. Heller · Director
  • Neil W. Flanzraich · Director
  • Noel W. Dunn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Martin Tolar, M.D., Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 30, 2020. Read the notice at the SEC.

equitySEC
Apr 2019$6 MNo. 5$2 to $10 million

Alzheon, Inc.: Raise no. 5, Apr 2019

Investors in this round

13 investors had bought by the notice of Jan 15, 2020: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Conversion of Convertible Promissory Notes
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth A. Mace · Executive Officer · Treasurer/VP Finance
  • Martin Tolar, M.D., Ph.D. · Director, Executive Officer · President and Chief Executive Officer
  • David W. Nikodem, Ph.D. · Director
  • Diane K. Jorkasky, M.D. · Director
  • Jordan W. Heller · Director
  • Neil W. Flanzraich · Director
  • Noel W. Dunn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount and Total Amount Sold also include the conversion of Promissory Notes.”

Signed by Martin Tolar, M.D., Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 15, 2020. Read the notice at the SEC.

equitySEC
May 2017$20 MNo. 4$10 to $50 million

Alzheon, Inc.: Raise no. 4, May 2017

Investors in this round

81 investors had bought by the notice of Sep 5, 2018: 81 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$189,955
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth A. Mace · Executive Officer
  • Martin Tolar · Executive Officer, Director
  • David Nikodem · Director
  • Dennis Langer · Director
  • Franz Hefti · Director
  • Jean-Pierre Garnier · Director
  • Neil W. Flanzraich · Director
  • Scott Minick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • CIM Securities, LLC · New York, New YorkSold in CA, CO, DE, FL, IL, MA, MD, NJ, NY, TX, WY

Remarks in the notice

  • On the amounts: “Total Offering Amount and Total Amount Sold also include the conversion of Promissory Notes.”

Signed by Martin Tolar, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Sep 5, 2018. Read the notice at the SEC.

equitySEC
Feb 2016$1 MNo. 3Under $2 million

Alzheon, Inc.: Raise no. 3, Feb 2016

Investors in this round

3 investors had bought by the notice of Feb 26, 2016: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $5 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$78,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ken Mace · Executive Officer
  • Martin Tolar · Executive Officer, Director
  • David Nikodem · Director
  • Dennis Langer · Director
  • Franz Hefti · Director
  • Jean-Pierre Garnier · Director
  • Scott Minick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • CIM Securities, LLC (CRD 120852) · New York, New YorkSold in CA, CO, FL, IL, MA, MD, NY, TX, WY

Signed by Martin Tolar, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 26, 2016. Read the notice at the SEC.

debt, optionsSEC
Jul 2015$7 MNo. 2$2 to $10 million

Alzheon, Inc.: Raise no. 2, Jul 2015

Investors in this round

26 investors had bought by the notice of Jul 27, 2015: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$402,344
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Hey · Executive Officer
  • Martin Tolar · Executive Officer, Director
  • Michael Aceti · Executive Officer
  • Robert Silverman · Executive Officer
  • David Nikodem · Director
  • Franklin Berger · Director
  • Franz Hefti · Director
  • Jean-Pierre Sommadossi · Director
  • Menghis Bairu · Director
  • Scott Minick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Brookline Group, LLC (CRD 153587) · Birmingham, AlabamaSold in AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, ID, IL, IN, KS, LA, MA, MD, ME, MI, MN, MO, MS, NC, NE, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, TN, TX, UT, VA, WA, WI, WV, WY

Signed by Martin Tolar, President. Source: SEC Form D, newest notice filed Jul 27, 2015. Read the notice at the SEC.

debt, optionsSEC
Dec 2014$7 MNo. 1$2 to $10 million

Alzheon, Inc.: Raise no. 1, Dec 2014

Investors in this round

60 investors had bought by the notice of Feb 25, 2015: 60 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$720,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Hey · Executive Officer
  • Martin Tolar · Executive Officer, Director
  • Michael Aceti · Executive Officer
  • David Nikodem · Director
  • Franklin Berger · Director
  • Franz Hefti · Director
  • Jean-Pierre Sommadossi · Director
  • Menghis Bairu · Director
  • Scott Minick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Brookline Group, LLC (CRD 153587) · Birmingham, AlabamaSold in AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, ID, IL, IN, KS, LA, MA, MD, ME, MI, MN, MO, MS, NC, NE, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, TN, TX, UT, VA, WA, WI, WV, WY

Remarks in the notice

  • On the use of proceeds: “The Company shall use some of the offering proceeds to pay salaries to executive officers in the ordinary course of business but shall not make any transaction based payments in connection with the offering.”

Signed by Martin Tolar, President. Source: SEC Form D and 1 amendment, newest notice filed Feb 25, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Alzheon, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2026).

    SEC Form D · Sep 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2026

That is all the official record says: Alzheon, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Alzheon, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 9 rounds above had up to 81 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Alzheon, Inc.
NameRoleNamed in
Adem K. AlbayrakChief Data OfficerSep 2026
Aidan K. Power, MRCPsychChief Development OfficerSep 2026
John K. Hey, Ph.D.Chief Scientific OfficerSep 2026
Kenneth K. MaceTreasurer and Chief Financial OfficerSep 2026
Martin Tolar, M.D., Ph.D.President and Chief Executive OfficerSep 2026
Susan K. Abushakra, M.D.Chief Medical OfficerSep 2026
Adem E. AlbayrakChief Data OfficerFeb 2025
Glenn E. PaulyChief Commercial OfficerFeb 2025
Kenneth A. MaceTreasurer and Chief Financial OfficerFeb 2025
Martin TolarExecutive officerSep 2018
Ken MaceExecutive officerJun 2017
John HeyExecutive officerJul 2015
Michael AcetiExecutive officerJul 2015
Robert SilvermanExecutive officerJul 2015
Mark VersavelExecutive officerJan 2015
Christopher Noel DunnDirectorSep 2026
Diane K. Jorkasky, M.D.DirectorSep 2026
Gino K. SantiniDirectorSep 2026
Jordan W. HellerDirectorSep 2026
Martin Tolar, M.D., Ph.D.President and Chief Executive OfficerSep 2026
Muneer K. SatterDirectorSep 2026
Neil W. FlanzraichDirectorSep 2026
Muneer E. SatterDirectorFeb 2025
Muneer E. SateerDirectorJan 2025
Noel W. DunnDirectorSep 2020
David W. Nikodem, Ph.D.DirectorJan 2020
David NikodemDirectorSep 2018
Dennis LangerDirectorSep 2018
Franz HeftiDirectorSep 2018
Jean-Pierre GarnierDirectorSep 2018
Martin TolarDirectorSep 2018
Scott MinickDirectorSep 2018
Franklin BergerDirectorJul 2015
Jean-Pierre SommadossiDirectorJul 2015
Menghis BairuDirectorJul 2015